Cargando…

Developing a Kinase-Specific Target Selection Method Using a Structure-Based Machine Learning Approach

INTRODUCTION: Despite recent advances in the drug discovery field, developing selective kinase inhibitors remains a complicated issue for a number of reasons, one of which is that there are striking structural similarities in the ATP-binding pockets of kinases. OBJECTIVE: To address this problem, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Afanasyeva, Arina, Nagao, Chioko, Mizuguchi, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719317/
https://www.ncbi.nlm.nih.gov/pubmed/33293834
http://dx.doi.org/10.2147/AABC.S278900
Descripción
Sumario:INTRODUCTION: Despite recent advances in the drug discovery field, developing selective kinase inhibitors remains a complicated issue for a number of reasons, one of which is that there are striking structural similarities in the ATP-binding pockets of kinases. OBJECTIVE: To address this problem, we have designed a machine learning model utilizing various structure-based and energy-based descriptors to better characterize protein–ligand interactions. METHODS: In this work, we use a dataset of 104 human kinases with available PDB structures and experimental activity data against 1202 small-molecule compounds from the PubChem BioAssay dataset “Navigating the Kinome”. We propose structure-based interaction descriptors to build activity predicting machine learning model. RESULTS AND DISCUSSION: We report a ligand-oriented computational method for accurate kinase target prioritizing. Our method shows high accuracy compared to similar structure-based activity prediction methods, and more importantly shows the same prediction accuracy when tested on the special set of structurally remote compounds, showing that it is unbiased to ligand structural similarity in the training set data. We hope that our approach will be useful for the development of novel highly selective kinase inhibitors.